111 related articles for article (PubMed ID: 2595744)
1. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks.
Larsen NE; Hansen LB
Ther Drug Monit; 1989 Nov; 11(6):642-6. PubMed ID: 2595744
[TBL] [Abstract][Full Text] [Related]
2. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
[TBL] [Abstract][Full Text] [Related]
3. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
[TBL] [Abstract][Full Text] [Related]
4. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO
Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204
[TBL] [Abstract][Full Text] [Related]
5. Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications.
Knudsen P; Hansen LB; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():11-4. PubMed ID: 3865500
[TBL] [Abstract][Full Text] [Related]
6. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
7. [Therapy control of perphenazine. 2. Clinical aspects].
Kjeldsen CS; Larsen NE; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Klitgaard NA; Krarup G
Ugeskr Laeger; 1991 Aug; 153(34):2339-43. PubMed ID: 1897043
[TBL] [Abstract][Full Text] [Related]
8. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
9. Depot perphenazine decanoate and enanthate for schizophrenia.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001717. PubMed ID: 10796445
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic implications of different oil vehicles used in depot neuroleptic treatment.
Knudsen P; Hansen LB; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():7-10. PubMed ID: 3865501
[TBL] [Abstract][Full Text] [Related]
11. [The effect of serum monitoring on concentration of perphenazine and zuclopenthixole].
Thomsen K; Olesen OV; Poulsen JH
Ugeskr Laeger; 1993 Aug; 155(32):2443-8. PubMed ID: 8356762
[TBL] [Abstract][Full Text] [Related]
12. Oral intake of perphenazine decanoate.
Larsen NE
Ther Drug Monit; 1998 Dec; 20(6):724. PubMed ID: 9853996
[No Abstract] [Full Text] [Related]
13. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
Hansen LB; Larsen NE; Vestergård P
Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.
Hansen LB; Larsen NE
Psychopharmacology (Berl); 1985; 87(1):16-9. PubMed ID: 3933033
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
Hansen LB; Larsen NE
Psychopharmacology (Berl); 1977 Jul; 53(2):127-30. PubMed ID: 408838
[TBL] [Abstract][Full Text] [Related]
16. A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.
Talvik M; Nordström AL; Larsen NE; Jucaite A; Cervenka S; Halldin C; Farde L
Psychopharmacology (Berl); 2004 Sep; 175(2):148-53. PubMed ID: 15007534
[TBL] [Abstract][Full Text] [Related]
17. [Therapy control of perphenazine in paranoid conditions. 1. Organizational aspects].
Rask PH; Krarup G; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Kjeldsen CS; Klitgaard NA
Ugeskr Laeger; 1991 Aug; 153(34):2336-9. PubMed ID: 1897042
[TBL] [Abstract][Full Text] [Related]
18. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.
Linnet K; Wiborg O
Clin Pharmacol Ther; 1996 Jul; 60(1):41-7. PubMed ID: 8689810
[TBL] [Abstract][Full Text] [Related]
19. Dose-response relationships of perphenazine in the treatment of acute psychoses.
Hansen LB; Larsen NE; Gulmann N
Psychopharmacology (Berl); 1982; 78(2):112-5. PubMed ID: 6817364
[TBL] [Abstract][Full Text] [Related]
20. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
